Company Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases.
The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates.
The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.
Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 284 |
| CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Contact Details
Address: 1700 Owens Street, Suite 205 San Francisco, California 94158 United States | |
| Phone | (415) 660-5320 |
| Website | nurixtx.com |
Stock Details
| Ticker Symbol | NRIX |
| Exchange | NASDAQ |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001549595 |
| CUSIP Number | 67080M103 |
| ISIN Number | US67080M1036 |
| Employer ID | 27-0838048 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | Chief Executive Officer, President and Director |
| Johannes Van Houte | Chief Financial Officer |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer |
| Dr. John Kuriyan Ph.D. | Founder and Member of Scientific Advisory Board |
| Michael Rapé Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Arthur Weiss M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Rita Kwong | Senior Accounting Manager |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary and Chief Compliance Officer |
| Eric C. Schlezinger J.D. | Chief People Officer |
| Dr. Jason Kantor Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 424B5 | Filing |
| Apr 11, 2024 | 424B5 | Filing |
| Apr 10, 2024 | 10-Q | Quarterly Report |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Mar 27, 2024 | ARS | Filing |
| Mar 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2024 | 8-K | Current Report |